'For quarter ended June 2024, standalone Net sales (including other operating income) of RPG Life Sciences has increased 11.94% to Rs 165.42 crore compared to quarter ended June 2023. Operating profit margin has jumped from 21.82% to 23.62%, leading to 21.18% rise in operating profit to Rs 39.07 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 21.05% to 19.31%. Purchase of finished goods cost rose from 11.51% to 14.84%. Employee cost decreased from 22.66% to 19.53%. Other expenses rose from 22.50% to 23.02%.
Other income up 30.94% to Rs 2.37 crore. PBIDT rose 21.70% to Rs 41.44 crore. Provision for interest up 114.29% to Rs 0.15 crore.
PBDT rose 21.51% to Rs 41.29 crore. Provision for depreciation rose 25.65% to Rs 5.29 crore.
Profit before tax grew 20.93% to Rs 36.00 crore. Provision for tax wa...
Pleaselogin & subscribe to view the full report.
More Reports
-
(01-Mar-2025)
Foseco India
OP up 17%
-
(28-Feb-2025)
Schaeffler India
Maintains double digit revenue growth and stable OPM
-
(28-Feb-2025)
Sanofi India
OP up 18.78%
-
(28-Feb-2025)
KSB
Net up 33% largely on higher sales, higher OI and lower taxation
|
|